FULCRUM THERAPEUTICS, INC.
26 Landsdowne Street
Cambridge, MA 02139
June 24, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Fulcrum Therapeutics, Inc. |
Registration Statement on Form S-1
File No. 333-239353
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-239353), so that it may become effective at 4:00 p.m. Eastern time on June 26, 2020, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours,
FULCRUM THERAPEUTICS, INC. | ||
| By: | /s/ Robert J. Gould | |
| Name: Title: |
Robert J. Gould President and Chief Executive Officer | |
| cc: | Lia Der Marderosian |
Wilmer Cutler Pickering Hale and Dorr LLP